nitrofurantoin monohydrate/macrocrystalline capsules — Competitive Intelligence Brief

nitrofurantoin monohydrate/macrocrystalline capsules (nitrofurantoin monohydrate/macrocrystalline capsules) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitrofuran antibiotic. Area: Infectious Disease.

marketed Nitrofuran antibiotic Bacterial DNA and ribosomal proteins (non-specific after activation) Infectious Disease Small molecule

Target snapshot

nitrofurantoin monohydrate/macrocrystalline capsules (nitrofurantoin monohydrate/macrocrystalline capsules) — University of California, San Diego. Nitrofurantoin is reduced by bacterial enzymes to reactive intermediates that damage bacterial DNA and proteins, leading to cell death.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
nitrofurantoin monohydrate/macrocrystalline capsules TARGET	nitrofurantoin monohydrate/macrocrystalline capsules	University of California, San Diego	marketed	Nitrofuran antibiotic	Bacterial DNA and ribosomal proteins (non-specific after activation)
Oral nitrofurantoin monohydrate/macrocrystals	Oral nitrofurantoin monohydrate/macrocrystals	NICHD Global Network for Women's and Children's Health	phase 3	Nitrofuran antibiotic	Bacterial DNA and RNA synthesis; bacterial nitroreductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nitrofuran antibiotic class)

1. NICHD Global Network for Women's and Children's Health · 1 drug in this class
2. University of California, San Diego · 1 drug in this class